Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612887 | 0.85 | P4HB (0.49) | P4HBESR1HDAC1 | |
| SCHEMBL23810520 | 0.82 | P4HB (0.59) | P4HBNR1H4ESR1AAK1USP30 | |
| SCHEMBL30188658 | 0.78 | AAK1 (0.43) | AAK1 | |
| SCHEMBL21612866 | 0.74 | CA9 (0.36) | ESR1 | |
| SCHEMBL15518178 | 0.73 | LIPG (0.40) | — | |
| SCHEMBL23321023 | 0.73 | BACE1 (0.31) | AAK1 | |
| SCHEMBL30188549 | 0.72 | FFAR1 (0.42) | USP30 | |
| SCHEMBL21612867 | 0.72 | CA1 (0.35) | AAK1 | |
| SCHEMBL30628949 | 0.72 | P4HB (0.46) | P4HBNR1H4ESR1AAK1USP30 | |
| SCHEMBL23801191 | 0.71 | HIF1A (0.41) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | P4HB 2886/4885NR1H4 2098/4885ESR1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.